Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of “Hold” from Brokerages

by · The Cerbat Gem

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been given an average rating of “Hold” by the seven brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $4.25.

Several research firms recently issued reports on INO. HC Wainwright reduced their target price on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a report on Monday, June 1st. Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings lowered shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th.

View Our Latest Research Report on Inovio Pharmaceuticals

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INO. MCF Advisors LLC purchased a new stake in Inovio Pharmaceuticals in the 3rd quarter worth approximately $26,000. SG Americas Securities LLC bought a new position in Inovio Pharmaceuticals in the 3rd quarter worth approximately $27,000. Focus Partners Wealth bought a new position in Inovio Pharmaceuticals in the 3rd quarter worth approximately $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 18,160 shares during the period. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Stock Down 7.8%

NASDAQ INO opened at $1.07 on Friday. The company has a 50-day moving average price of $1.25 and a 200-day moving average price of $1.60. The firm has a market capitalization of $88.03 million, a P/E ratio of -0.74 and a beta of 1.49. Inovio Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02. As a group, equities research analysts anticipate that Inovio Pharmaceuticals will post -0.97 EPS for the current year.

About Inovio Pharmaceuticals

(Get Free Report)

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

See Also